Literature DB >> 6491376

The biochemistry of opsonization: central role of the reactive thiolester of the third component of complement.

M K Hostetter, R A Krueger, D J Schmeling.   

Abstract

In these studies, we have defined the mechanism by which the opsonic fragment of the third component of complement (C3) binds to pathogenic bacteria. With use of purified human C3 to reconstitute the alternative pathway in human serum in which both C3 and C4 had been chemically inactivated, we showed that opsonization of pathogenic serotypes of Streptococcus pneumoniae (serotypes 3, 4, 6A, 14, and 18C) requires the reactive thiolester of native C3. When purified human C3 (thiolester intact) is added to serum deficient in C3 and C4, phagocytic uptake of 3H-labeled pneumococci by polymorphonuclear leukocytes from normal adults is fully reconstituted. However, hydrolysis of the thiolester or reaction of the thiolester with the inhibitor methylamine abolishes opsonization and phagocytosis. Finally, by characterizing those C3 fragments released from pneumococcal surfaces after treatment with 1.0 M hydroxylamine, we have defined a role for covalent-bond formation in the opsonic interaction. Therefore, the presence of the reactive thiolester of C3 is an absolute requirement for the opsonic and covalent binding of the C3b molecule to pathogenic bacteria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491376     DOI: 10.1093/infdis/150.5.653

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Influence of serotype of group B streptococci on C3 degradation.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

2.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Outer membrane protein binding sites of complement component 3 during opsonization of Haemophilus influenzae.

Authors:  S V Hetherington; C C Patrick; E J Hansen
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 4.  Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  P Densen
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

5.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.

Authors:  M K Hostetter; G M Johnson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces.

Authors:  R M Hamadeh; G A Jarvis; U Galili; R E Mandrell; P Zhou; J M Griffiss
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

7.  Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinase.

Authors:  S L Reed; I Gigli
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

8.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 9.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 10.  The iC3b receptor of Candida albicans and its roles in pathogenesis.

Authors:  Margaret K Hostetter
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.